^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PVX2

i
Other names: PVX2, TA-CIN Vaccine
Associations
Company:
PapiVax
Drug class:
Immunostimulant
Related drugs:
Associations
4ms
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer (clinicaltrials.gov)
P1, N=14, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Mar 2024 --> Dec 2024
Trial primary completion date
|
PVX2
5ms
PVX-2: Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL (clinicaltrials.gov)
P2, N=16, Terminated, PapiVax Biotech, Inc. | N=134 --> 16 | Recruiting --> Terminated; Slow recruitment/funding
Enrollment change • Trial termination • Cytology
|
PVX2
over1year
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer (clinicaltrials.gov)
P1, N=14, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
PVX2